RDD Pharma Announces Positive Results in a Double-Blind Placebo-Controlled Crossover Phase 2a Study in Fecal Incontinence in Patients with Spinal Cord Injury
NEW YORK, Oct. 16, 2015 /PRNewswire/ --RDD Pharma announced today positive results in evaluating the safety and efficacy of RDD-0315 for the treatment of fecal incontinence in patients with spinal cord injury. Preliminary analysis of the data indicates a statistically significant decrease in the number of unwanted bowel movements in patients treated with RDD-0315 compared to placebo in a cross-over study.
"We are thrilled with the positive results of this Phase 2a study and the potential of a treatment such as RDD-0315 for patients who suffer from fecal incontinence," said Nir Barak, Chief Medical Officer of RDD Pharma. "RDD is filling the unmet need of managing fecal incontinence in adults with central neurological diseases."
Dr. Nir Barak, will be presenting these results at a podium presentation at the American Congress of Rehabilitation Medicine (ACRM) in Dallas, Texas on October 28, 2015.
About RDD Pharma
RDD is a privately held specialty pharma company focused on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders. RDD Pharma's lead product for the treatment of pain associated with anal fissure is starting Phase 3 in Europe in Q4, 2015. RDD-0315 for fecal incontinence will begin a Phase 2b in 2016. Products currently under development at RDD are expected to reach the market in two to six years. www.rddpharma.com
About Fecal Incontinence Associated with Spinal Cord Injury, (SCI)
There are an estimated 276,000 people in the U.S. who have SCI with approximately 12,500 new SCI cases per year. A spinal cord injury may interrupt communication between the nerves in the spinal cord that control bladder and bowel function and the brain, causing incontinence.
Loss of bowel control causes embarrassment, even humiliation. Bowel dysfunction, secondary to spinal cord injury, reduces quality of life. Fecal incontinence in SCI is the #1 risk factor for development of pressure ulcers.
Contact:
Jason Laufer
CEO
[email protected]
+1-973-723-9000
Jennifer Filbey, Ph.D.
VP, Business & Corporate Development
[email protected]
+1-256-417-8568
Logo - http://photos.prnewswire.com/prnh/20151016/277630LOGO
SOURCE RDD Pharma
Share this article